LG Chem Holds Symposium on Sharing Latest Academic Information on Nepoxil, Treatment for Hyperphosphatemia
Sep 10, 2025
|
Nepoxil (component; ferric citrate hydrate), an iron-based non-calcium phosphorus binder, simultaneously provides phosphorus reduction and additional iron supplementation.
At this symposium, major revisions and treatment methods for "2025 KDIGO (International Kidney Society) anemia are being reviewed by domestic nephrotic physicians, and effective hyperphosphatemia treatment solutions based on nephrotic clinical results were presented.
KDIGO announced that it will revise the iron parameter monitoring cycle in hemodialysis patients from 3 months to 1 month, and actively recommends the use of an intravenous (IV) formulation in hemodialysis patients with chronic kidney disease (stage 5).
LG Chem emphasized that nefoxil, an iron-based non-calcium phosphorus binder, is a product that meets the newly revised treatment guidelines and is an ideal hyperphosphatemia treatment that adds additional iron supplementation to the serum phosphorus control effect. He then confirmed that even a smaller dose of Nepoxil clinical trials in Japan had a similar effect to that of Sevelamer, the treaty, and said that serum phosphorus levels at 12 weeks of administration reached less than the therapeutic target of 5.5 mg/dL. In addition, it was analyzed that a significant increase in iron parameters, which is an additional effect, leads to a decrease in the use of iron and hematopoietic agents, and ultimately, nefoxil may have a positive effect on lowering the economic burden on hemodialysis patients.
In addition to Nephoxil, the symposium was followed by academic presentations related to long-term hematopoietic drugs 'Nesp' and secondary hyperparathyroidism treatments 'Alkedia'.
"Nepoxil has a phosphorus control effect similar to that of existing therapeutic ingredients, but it also benefits anemia treatment through additional iron supplementation effects," an LG Chem marketing official said. "We will continue to discover and provide effective and accessible treatment options for improving the quality of life of patients with chronic kidney disease in Korea."
This article was translated by Naver AI translator.
